详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

IMPROVED EFFICACY AND SAFETY OF ZANUBRUTINIB VERSUS IBRUTINIB IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (R/R CLL) IN CHINA: A SUBGROUP OF ALPINE

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]National Clinical Research Center for Blood Diseases and State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Experimental Hematology, Tianjin, China. [2]Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Hematology, Zhengzhou, China. [3]National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College and Tianjin Institutes of Health Science, State Key Laboratory of Experimental Hematology, Tianjin, China. [4]West China Hospital, Sichuan University, Hematology, Sichuan, China. [5]Jiangsu Province Hospital, Hematology, Zhejiang, China. [6]The First Hospital of Zhejiang Province, Hematology, Zhejiang, China. [7]Peking Union Medical College Hospital, Hematology, Beijing, China. [8]Union Hospital of Tongji Medical College, Hematology, Wuhan, China. [9]Fujian Medical University Union Hospital, Hematology, Fuzhou, China. [10]Nanfang Hospital of Southern Medical University, Hematology, Guangzhou, China. [11]Tongji Hospital of Tongji University, Hematology, Wuhan, China. [12]Shengjing Hospital of China Medical University, Hematology, Shenyang, China. [13]Zhongshan Hospital of Fudan University, Hematology, Shanghai, China. [14]Peking University Third Hospital, Hematology, Beijing, China. [15]The First Hospital of Jilin University, Hematology, Oncology, Changchun, China. [16]The First Affiliated Hospital of Wenzhou Medical University, Hematology, Zhejiang, China. [17]Beijing Friendship Hospital, Hematology, Beijing, China. [18]Tianjin Medical University Cancer Institute & Hospital, Hematology, Oncology, Tianjin, China. [19]Quanzhou First Hospital of Fujian Province, Hematology, Quanzhou, China. [20]Anhui Provincial Hospital, Hematology, Hefei, China. [21]The First Affiliated Hospital of Nanchang University, Hematology, Nanchang, China. [22]The Affiliated Hospital of Xuzhou Medical University, Hematology, Jiangsu, China. [23]Guangdong Provincial People's Hospital, Hematology, Guangzhou, China. [24]BeiGene (Shanghai) Co., Ltd, Shanghai, China. [25]Beigene International, GmbH, Basel, Switzerland. [26]BeiGene USA, Inc., San Mateo, California, USA. [27]Dana-Farber Cancer Institute, Boston, Massachusetts, USA.

出处：

DOI：

ISSN：

关键词： Chronic Lymphocytic Leukemia (CLL) Molecular Targeted Therapies

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2023]版：

大类 | 4 区医学

小类 | 4 区血液学 4 区肿瘤学

最新[2023]版：

大类 | 4 区医学

小类 | 4 区血液学 4 区肿瘤学

第一作者：

第一作者机构： [1]National Clinical Research Center for Blood Diseases and State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Experimental Hematology, Tianjin, China.

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Improved efficacy and safety of zanubrutinib versus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) in China: a subgroup of ALPINE [2]Molecular targeted therapies for cutaneous squamous cell carcinoma: recent developments and clinical implications [3]Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001) [4]Targeting regulated cell death (RCD) with small-molecule compounds in triple-negative breast cancer: a revisited perspective from molecular mechanisms to targeted therapies. [5]医院后勤精细化管理策略研究 [6]个性化目标教学在神经外科护理实习生带教中的应用 [7]纳米增强免疫比浊法和高效液相色谱法检测化疗患者5-氟尿嘧啶血药浓度的比较 [8]徒手淋巴引流对乳腺癌术后淋巴水肿的治疗效果分析 [9]护理干预在减轻妇科恶性肿瘤腹部术后疼痛中的效果 [10]心理护理对肿瘤介入治疗患者生活质量的影响